Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma
BackgroundProteinase 3 (PRTN3) has been recognized as a crucial target for anti-neutrophil cytoplasmic autoantibody. However, the relationship between anti-PRTN3 autoantibody and cancer remains largely unexplored.MethodsImmunohistochemistry was used to detect the level of PRTN3 in lung adenocarcinom...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534078/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850195520109150208 |
|---|---|
| author | Yutong Li Yutong Li Yutong Li Linhong Wang Linhong Wang Linhong Wang Fengqi Chen Fengqi Chen Fengqi Chen Rulan Liao Rulan Liao Rulan Liao Jing Li Jing Li Jing Li Xiaobin Cao Xiaobin Cao Xiaobin Cao Songyun Ouyang Liping Dai Liping Dai Liping Dai Liping Dai Renle Du Renle Du Renle Du Renle Du |
| author_facet | Yutong Li Yutong Li Yutong Li Linhong Wang Linhong Wang Linhong Wang Fengqi Chen Fengqi Chen Fengqi Chen Rulan Liao Rulan Liao Rulan Liao Jing Li Jing Li Jing Li Xiaobin Cao Xiaobin Cao Xiaobin Cao Songyun Ouyang Liping Dai Liping Dai Liping Dai Liping Dai Renle Du Renle Du Renle Du Renle Du |
| author_sort | Yutong Li |
| collection | DOAJ |
| description | BackgroundProteinase 3 (PRTN3) has been recognized as a crucial target for anti-neutrophil cytoplasmic autoantibody. However, the relationship between anti-PRTN3 autoantibody and cancer remains largely unexplored.MethodsImmunohistochemistry was used to detect the level of PRTN3 in lung adenocarcinoma (LUAD) tissue array. Enzyme-linked immunosorbent assay was conducted to measure anti-PRTN3 IgG and IgM autoantibodies in plasma from patients with early- and advanced-stage LUAD, benign pulmonary nodules (BPN) and normal control (NC). Western blotting and immunofluorescence staining were performed to confirm the presence of plasma immune response to PRTN3.ResultsPRTN3 protein was highly expressed in LUAD tissues. Elevated plasma levels of anti-PRTN3 IgG and IgM autoantibodies were also detected in LUAD, especially in early LUAD. The AUC of anti-PRTN3 IgG autoantibodies in the diagnosis of early LUAD from NC was 0.782, and from BPN was 0.761. When CEA and anti-PRTN3 autoantibodies were combined, the AUC for the diagnosis of early LUAD was significantly higher than that of CEA alone. The presence of a plasma immune response to PRTN3 in LUAD was also confirmed.ConclusionAnti-PRTN3 IgG and IgM autoantibodies maybe early biomarkers to differentiate LUAD from NC and BPN. |
| format | Article |
| id | doaj-art-879eb3f262d344b0b0a3b0255ba601fd |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-879eb3f262d344b0b0a3b0255ba601fd2025-08-20T02:13:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15340781534078Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinomaYutong Li0Yutong Li1Yutong Li2Linhong Wang3Linhong Wang4Linhong Wang5Fengqi Chen6Fengqi Chen7Fengqi Chen8Rulan Liao9Rulan Liao10Rulan Liao11Jing Li12Jing Li13Jing Li14Xiaobin Cao15Xiaobin Cao16Xiaobin Cao17Songyun Ouyang18Liping Dai19Liping Dai20Liping Dai21Liping Dai22Renle Du23Renle Du24Renle Du25Renle Du26Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaDepartment of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Laboratory of Tumor Epidemiology & State Key Laboratory of Esophageal Cancer Prevention, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaBeijing Genomics Institution (BGI) College, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, ChinaHenan Key Laboratory for Pharmacology of Liver Diseases, Zhengzhou University, Zhengzhou, Henan, ChinaBackgroundProteinase 3 (PRTN3) has been recognized as a crucial target for anti-neutrophil cytoplasmic autoantibody. However, the relationship between anti-PRTN3 autoantibody and cancer remains largely unexplored.MethodsImmunohistochemistry was used to detect the level of PRTN3 in lung adenocarcinoma (LUAD) tissue array. Enzyme-linked immunosorbent assay was conducted to measure anti-PRTN3 IgG and IgM autoantibodies in plasma from patients with early- and advanced-stage LUAD, benign pulmonary nodules (BPN) and normal control (NC). Western blotting and immunofluorescence staining were performed to confirm the presence of plasma immune response to PRTN3.ResultsPRTN3 protein was highly expressed in LUAD tissues. Elevated plasma levels of anti-PRTN3 IgG and IgM autoantibodies were also detected in LUAD, especially in early LUAD. The AUC of anti-PRTN3 IgG autoantibodies in the diagnosis of early LUAD from NC was 0.782, and from BPN was 0.761. When CEA and anti-PRTN3 autoantibodies were combined, the AUC for the diagnosis of early LUAD was significantly higher than that of CEA alone. The presence of a plasma immune response to PRTN3 in LUAD was also confirmed.ConclusionAnti-PRTN3 IgG and IgM autoantibodies maybe early biomarkers to differentiate LUAD from NC and BPN.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534078/fullautoantibodybiomarkerlung adenocarcinomaPRTN3early diagnosis |
| spellingShingle | Yutong Li Yutong Li Yutong Li Linhong Wang Linhong Wang Linhong Wang Fengqi Chen Fengqi Chen Fengqi Chen Rulan Liao Rulan Liao Rulan Liao Jing Li Jing Li Jing Li Xiaobin Cao Xiaobin Cao Xiaobin Cao Songyun Ouyang Liping Dai Liping Dai Liping Dai Liping Dai Renle Du Renle Du Renle Du Renle Du Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma Frontiers in Immunology autoantibody biomarker lung adenocarcinoma PRTN3 early diagnosis |
| title | Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma |
| title_full | Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma |
| title_fullStr | Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma |
| title_full_unstemmed | Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma |
| title_short | Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma |
| title_sort | plasma anti prtn3 igg and igm autoantibodies novel biomarkers for early detection of lung adenocarcinoma |
| topic | autoantibody biomarker lung adenocarcinoma PRTN3 early diagnosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1534078/full |
| work_keys_str_mv | AT yutongli plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT yutongli plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT yutongli plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT linhongwang plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT linhongwang plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT linhongwang plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT fengqichen plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT fengqichen plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT fengqichen plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT rulanliao plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT rulanliao plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT rulanliao plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT jingli plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT jingli plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT jingli plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT xiaobincao plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT xiaobincao plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT xiaobincao plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT songyunouyang plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT lipingdai plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT lipingdai plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT lipingdai plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT lipingdai plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT renledu plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT renledu plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT renledu plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma AT renledu plasmaantiprtn3iggandigmautoantibodiesnovelbiomarkersforearlydetectionoflungadenocarcinoma |